<p>Celcuity, Inc.（納斯達克代碼：CELC - 獲取免費報告）的股票在目前覆蓋該公司的五家研究公司中獲得了 “買入” 的共識評級，MarketBeat.com 報道。五位研究分析師對該股票給予了買入推薦。在過去一年中更新了對該股票覆蓋的經紀人中，平均一年價格目標為 56.50 美元。</p>
<p>CELC 最近成為幾份分析師報告的主題。Needham &amp; Company LLC 將 Celcuity 的股票目標價從 74.00 美元下調至 70.00 美元，並在 8 月 15 日的報告中對該股票設定了 “買入” 評級。Stifel Nicolaus 於 7 月 1 日的研究報告中開始覆蓋 Celcuity 的股票。他們對該股票設定了 “買入” 評級和 30.00 美元的價格目標。Leerink Partners 在 7 月 28 日的研究報告中將 Celcuity 的股票目標價從 28.00 美元上調至 60.00 美元，並給予該股票 “跑贏大盤” 的評級。HC Wainwright 在 8 月 18 日的研究報告中將 Celcuity 的股票目標價從 50.00 美元上調至 66.00 美元，並給予該股票 “買入” 評級。最後，Guggenheim 在週一的研究報告中開始覆蓋 Celcuity，並對該股票設定了 “買入” 評級。</p>
<p><strong>閲讀我們關於 CELC 的最新報告</strong></p>
<h2>Celcuity 股票表現</h2>
<p>Celcuity 股票在週一開盤價為 51.88 美元。Celcuity 的十二個月最低價為 7.57 美元，最高價為 63.06 美元。該股票的市值為 22 億美元，市盈率為-15.04，貝塔值為 0.72。公司的流動比率為 4.58，速動比率為 4.58，債務與股本比率為 2.24。該公司的 50 日移動平均價格為 42.86 美元，200 日移動平均價格為 22.13 美元。</p>
<p>Celcuity（納斯達克代碼：CELC - 獲取免費報告）最近於 8 月 14 日宣佈了其季度財報。公司報告每股收益為（1.04 美元），低於分析師的共識預期（0.90 美元）14 美分。整體來看，研究分析師預計 Celcuity 在本年度的每股收益為-2.62 美元。</p>
<h2>內部人士下注</h2>
<p>在其他 Celcuity 的新聞中，董事 David Dalvey 於 7 月 28 日出售了 100,000 股公司的股票。該股票以平均價格 43.98 美元出售，總價值為 4,398,000.00 美元。出售後，該董事在公司持有 125,000 股，價值約為 5,497,500 美元。這筆交易代表了他們持有股票的 44.44% 的減少。該出售在向證券交易委員會提交的文件中披露，您可以通過此鏈接訪問。15.78% 的股票由公司內部人士持有。</p>
<h2>Celcuity 的機構交易</h2>
<p>大型投資者最近增加或減少了對該公司的持股。Rhumbline Advisers 在第二季度將其在 Celcuity 的持股增加了 1.2%。Rhumbline Advisers 目前持有 42,697 股公司股票，價值 570,000 美元，此前在該期間購買了 503 股。Intech Investment Management LLC 在第二季度將其在 Celcuity 的持股增加了 5.2%。Intech Investment Management LLC 目前持有 14,855 股公司股票，價值 198,000 美元，此前在該期間購買了 734 股。BNP Paribas Financial Markets 在第二季度將其在 Celcuity 的持股增加了 78.9%。BNP Paribas Financial Markets 目前持有 2,647 股公司股票，價值 35,000 美元，此前在該期間購買了 1,167 股。GAMMA Investing LLC 在第一季度將其在 Celcuity 的持股增加了 1,237.4%。GAMMA Investing LLC 目前持有 1,324 股公司股票，價值 131,000 美元，此前在該期間購買了 1,225 股。最後，Tema Etfs LLC 在第二季度將其在 Celcuity 的持股增加了 8.9%。Tema Etfs LLC 目前持有 17,011 股公司股票，價值 227,000 美元，此前在該期間購買了 1,392 股。目前 63.33% 的股票由機構投資者和對沖基金持有。</p>
<h2>關於 Celcuity</h2>
<p>（獲取免費報告）</p>
<p>Celcuity Inc 是一家臨牀階段的生物技術公司，專注於開發針對美國各種實體腫瘤的靶向療法。公司的 CELsignia 診斷平台利用患者的活腫瘤細胞來識別驅動患者癌症的特定異常細胞過程及相關的靶向療法。</p>
<h2>瞭解更多</h2>
<ul>
<li>五隻我們更看好的股票，勝過 Celcuity</li>
<li>使用 MarketBeat 股息收益計算器</li>
<li>3 只被忽視的價值股，預計在利率下降時大幅上漲</li>
<li>最佳股票低於 5.00 美元</li>
<li>Hims &amp; Hers 股票因醫療保健降息狂潮而飆升</li>
<li>納斯達克股票交易所是什麼？</li>
<li>在美聯儲降息後，PNC 可能會迎來抵押貸款再融資熱潮</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0VMQw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0VMQw"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送電子郵件至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1000 美元在 Celcuity 嗎？</h2>
<p>在考慮 Celcuity 之前，你會想聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前立即購買……而 Celcuity 並不在名單上。</p>
<p>雖然 Celcuity 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

CELC

<p>Celcuity, Inc.（納斯達克代碼：CELC）獲得了五家研究公司的共識 “買入” 評級。平均一年目標價為 56.50 美元。最近的分析師報告顯示，Needham & Company 將其目標價從 74.00 美元下調至 70.00 美元，而 Leerink Partners 則將其目標價從 28.00 美元上調至 60.00 美元。Celcuity 的股票開盤價為 51.88 美元，12 個月的價格區間為 7.57 美元至 63.06 美元。該公司報告每股季度虧損為（1.04 美元），未能達到預期。機構投資者持有 63.33% 的股份，內部人士持有 15.78%</p>

<p>Shares of Celcuity, Inc. (NASDAQ:CELC - Get Free Report) have been given a consensus rating of &#34;Buy&#34; by the five research firms that are currently covering the company, MarketBeat.com reports. Five research analysts have rated the stock with a buy recommendation. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $56.50.</p>
<div class="lb-trans"><p>Celcuity, Inc.（納斯達克代碼：CELC - 獲取免費報告）的股票在目前覆蓋該公司的五家研究公司中獲得了 “買入” 的共識評級，MarketBeat.com 報道。五位研究分析師對該股票給予了買入推薦。在過去一年中更新了對該股票覆蓋的經紀人中，平均一年價格目標為 56.50 美元。</p>
</div><p>CELC has been the topic of several recent analyst reports. Needham &amp; Company LLC cut their price target on shares of Celcuity from $74.00 to $70.00 and set a &#34;buy&#34; rating on the stock in a report on Friday, August 15th. Stifel Nicolaus started coverage on shares of Celcuity in a research note on Tuesday, July 1st. They set a &#34;buy&#34; rating and a $30.00 price objective on the stock. Leerink Partners increased their price objective on shares of Celcuity from $28.00 to $60.00 and gave the stock an &#34;outperform&#34; rating in a research note on Monday, July 28th. HC Wainwright increased their price objective on shares of Celcuity from $50.00 to $66.00 and gave the stock a &#34;buy&#34; rating in a research note on Monday, August 18th. Finally, Guggenheim initiated coverage on Celcuity in a research report on Monday. They set a &#34;buy&#34; rating on the stock.</p>
<div class="lb-trans"><p>CELC 最近成為幾份分析師報告的主題。Needham &amp; Company LLC 將 Celcuity 的股票目標價從 74.00 美元下調至 70.00 美元，並在 8 月 15 日的報告中對該股票設定了 “買入” 評級。Stifel Nicolaus 於 7 月 1 日的研究報告中開始覆蓋 Celcuity 的股票。他們對該股票設定了 “買入” 評級和 30.00 美元的價格目標。Leerink Partners 在 7 月 28 日的研究報告中將 Celcuity 的股票目標價從 28.00 美元上調至 60.00 美元，並給予該股票 “跑贏大盤” 的評級。HC Wainwright 在 8 月 18 日的研究報告中將 Celcuity 的股票目標價從 50.00 美元上調至 66.00 美元，並給予該股票 “買入” 評級。最後，Guggenheim 在週一的研究報告中開始覆蓋 Celcuity，並對該股票設定了 “買入” 評級。</p>
</div><p><strong>Read Our Latest Report on CELC</strong></p>
<div class="lb-trans"><p><strong>閲讀我們關於 CELC 的最新報告</strong></p>
</div><h2>Celcuity Price Performance</h2>
<div class="lb-trans"><h2>Celcuity 股票表現</h2>
</div><p>Shares of Celcuity stock opened at $51.88 on Monday. Celcuity has a twelve month low of $7.57 and a twelve month high of $63.06. The stock has a market capitalization of $2.20 billion, a P/E ratio of -15.04 and a beta of 0.72. The company has a current ratio of 4.58, a quick ratio of 4.58 and a debt-to-equity ratio of 2.24. The business's fifty day moving average price is $42.86 and its 200 day moving average price is $22.13.</p>
<div class="lb-trans"><p>Celcuity 股票在週一開盤價為 51.88 美元。Celcuity 的十二個月最低價為 7.57 美元，最高價為 63.06 美元。該股票的市值為 22 億美元，市盈率為-15.04，貝塔值為 0.72。公司的流動比率為 4.58，速動比率為 4.58，債務與股本比率為 2.24。該公司的 50 日移動平均價格為 42.86 美元，200 日移動平均價格為 22.13 美元。</p>
</div><p>Celcuity (NASDAQ:CELC - Get Free Report) last announced its quarterly earnings results on Thursday, August 14th. The company reported ($1.04) earnings per share for the quarter, missing analysts' consensus estimates of ($0.90) by ($0.14). As a group, research analysts anticipate that Celcuity will post -2.62 earnings per share for the current year.</p>
<div class="lb-trans"><p>Celcuity（納斯達克代碼：CELC - 獲取免費報告）最近於 8 月 14 日宣佈了其季度財報。公司報告每股收益為（1.04 美元），低於分析師的共識預期（0.90 美元）14 美分。整體來看，研究分析師預計 Celcuity 在本年度的每股收益為-2.62 美元。</p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>內部人士下注</h2>
</div><p>In other Celcuity news, Director David Dalvey sold 100,000 shares of the firm's stock in a transaction that occurred on Monday, July 28th. The shares were sold at an average price of $43.98, for a total value of $4,398,000.00. Following the sale, the director owned 125,000 shares in the company, valued at approximately $5,497,500. This trade represents a 44.44% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which can be accessed through this link. 15.78% of the stock is owned by corporate insiders.</p>
<div class="lb-trans"><p>在其他 Celcuity 的新聞中，董事 David Dalvey 於 7 月 28 日出售了 100,000 股公司的股票。該股票以平均價格 43.98 美元出售，總價值為 4,398,000.00 美元。出售後，該董事在公司持有 125,000 股，價值約為 5,497,500 美元。這筆交易代表了他們持有股票的 44.44% 的減少。該出售在向證券交易委員會提交的文件中披露，您可以通過此鏈接訪問。15.78% 的股票由公司內部人士持有。</p>
</div><h2>Institutional Trading of Celcuity</h2>
<div class="lb-trans"><h2>Celcuity 的機構交易</h2>
</div><p>Large investors have recently added to or reduced their stakes in the business. Rhumbline Advisers increased its holdings in shares of Celcuity by 1.2% during the second quarter. Rhumbline Advisers now owns 42,697 shares of the company's stock valued at $570,000 after purchasing an additional 503 shares during the period. Intech Investment Management LLC increased its holdings in shares of Celcuity by 5.2% during the second quarter. Intech Investment Management LLC now owns 14,855 shares of the company's stock valued at $198,000 after purchasing an additional 734 shares during the period. BNP Paribas Financial Markets increased its stake in Celcuity by 78.9% during the 2nd quarter. BNP Paribas Financial Markets now owns 2,647 shares of the company's stock valued at $35,000 after buying an additional 1,167 shares during the period. GAMMA Investing LLC increased its stake in Celcuity by 1,237.4% during the 1st quarter. GAMMA Investing LLC now owns 1,324 shares of the company's stock valued at $131,000 after buying an additional 1,225 shares during the period. Finally, Tema Etfs LLC increased its stake in Celcuity by 8.9% during the 2nd quarter. Tema Etfs LLC now owns 17,011 shares of the company's stock valued at $227,000 after buying an additional 1,392 shares during the period. 63.33% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>大型投資者最近增加或減少了對該公司的持股。Rhumbline Advisers 在第二季度將其在 Celcuity 的持股增加了 1.2%。Rhumbline Advisers 目前持有 42,697 股公司股票，價值 570,000 美元，此前在該期間購買了 503 股。Intech Investment Management LLC 在第二季度將其在 Celcuity 的持股增加了 5.2%。Intech Investment Management LLC 目前持有 14,855 股公司股票，價值 198,000 美元，此前在該期間購買了 734 股。BNP Paribas Financial Markets 在第二季度將其在 Celcuity 的持股增加了 78.9%。BNP Paribas Financial Markets 目前持有 2,647 股公司股票，價值 35,000 美元，此前在該期間購買了 1,167 股。GAMMA Investing LLC 在第一季度將其在 Celcuity 的持股增加了 1,237.4%。GAMMA Investing LLC 目前持有 1,324 股公司股票，價值 131,000 美元，此前在該期間購買了 1,225 股。最後，Tema Etfs LLC 在第二季度將其在 Celcuity 的持股增加了 8.9%。Tema Etfs LLC 目前持有 17,011 股公司股票，價值 227,000 美元，此前在該期間購買了 1,392 股。目前 63.33% 的股票由機構投資者和對沖基金持有。</p>
</div><h2>About Celcuity</h2>
<div class="lb-trans"><h2>關於 Celcuity</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.</p>
<div class="lb-trans"><p>Celcuity Inc 是一家臨牀階段的生物技術公司，專注於開發針對美國各種實體腫瘤的靶向療法。公司的 CELsignia 診斷平台利用患者的活腫瘤細胞來識別驅動患者癌症的特定異常細胞過程及相關的靶向療法。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>瞭解更多</h2>
</div><ul>
<li>Five stocks we like better than Celcuity</li>
<li>Using the MarketBeat Dividend Yield Calculator</li>
<li>3 Overlooked Value Stocks Set to Surge as Rates Drop</li>
<li>Best Stocks Under $5.00</li>
<li>Hims &amp; Hers Stock Pushes to Highs on Healthcare Rate Cut Frenzy</li>
<li>What is the NASDAQ Stock Exchange?</li>
<li>After the Fed's Rate Cut, PNC Could See a Mortgage Refinance Boom</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 Celcuity</li>
<li>使用 MarketBeat 股息收益計算器</li>
<li>3 只被忽視的價值股，預計在利率下降時大幅上漲</li>
<li>最佳股票低於 5.00 美元</li>
<li>Hims &amp; Hers 股票因醫療保健降息狂潮而飆升</li>
<li>納斯達克股票交易所是什麼？</li>
<li>在美聯儲降息後，PNC 可能會迎來抵押貸款再融資熱潮</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0VMQw" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=CELC"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送電子郵件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Celcuity Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1000 美元在 Celcuity 嗎？</h2>
</div><p>Before you consider Celcuity, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Celcuity 之前，你會想聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Celcuity wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前立即購買……而 Celcuity 並不在名單上。</p>
</div><p>While Celcuity currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Celcuity 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Celcuity, Inc.（NASDAQ:CELC）被分析師給予 “買入” 平均評級